#ICYMI: Co-founder & CPO Lex Johnson joined @bradloncar on @BiotechTV, covering our first-in-class Flare platform, plus new #ASGCT2026 data on SEND, our novel T cell armoring strategy.
Watch below. biotechtv.com/post/asgct-202…
English
Dispatch Bio
51 posts
Dispatch Bio
@DispatchBio
On a mission to help create a world where all cancer patients can be cured
Philadelphia, PA Katılım Mayıs 2024
5 Takip Edilen66 Takipçiler
Our name, explained.
“Dispatch” reflects our dual approach: a tumor-specific virus delivers a Flare antigen, which then acts as a beacon to target therapeutics to find & clear #cancer cells, advancing a universal approach across solid tumors.
GIF
English
Proud to see our co-founder Carl June and founding chairman Jeff Marrazzo recognized as Disruptors of the Year by @ThePhilaCitizen, in honor of their contributions to founding Dispatch & work to translate breakthrough science into real impact for patients. thephiladelphiacitizen.org/recap-2026-cit…
English
At #ASGCT2026, we’ll present new preclinical data on SEND, a novel synthetic cytokine receptor with the potential to optimize safety and efficacy profiles of immunotherapy treatments. Learn more here: dispatchbio.com/news/dispatch-…
English
Proud to be part of the @parkerici network and share in their mission to advance scientific discovery into therapeutic progress. Here’s to continuing to work together to improve outcomes for people with cancer.
Read more below.
Parker Institute for Cancer Immunotherapy@parkerici
Thank you to @steveusdin1 and @BioCentury for covering PICI’s mission to close a key biotech gap by translating discovery into real therapies. BioCentury highlights Azalea Therapeutics, @AkamisBio, and PICI portfolio company, @DispatchBio, as powerful examples of PICI’s model in action. Read more here: biocentury.com/article/659073…
English
Congratulations to all of this year’s honorees. View more info here: bizjournals.com/philadelphia/n…
English
Thrilled to share that our co-founder & Chief Platform Officer has been featured in this year’s @PHLBizJournal's 40 Under 40.
This award reflects Lex’s leadership in advancing our mission and contributing to Philadelphia’s growing life sciences community.
English
We’re pleased to share that Chris Wiwi has been promoted to CTO at Dispatch.
An early member of our team, Chris has built and led our technical operations organization spanning CMC development and manufacturing. He will continue to do so as we enter the clinic. Congrats, Chris!
English
Register to hear about our presentation, among others, at sitcancer.org/edu/2026-sprin…
English
Dispatch will participate in the 2026 @sitcancer Spring Scientific in Tucson, in which our CSO, Barbra Sasu, PhD, will present on how synthetic antigen strategies may enable universal immunotherapies across solid tumors.
Looking forward to engaging with the IO community!
English
We were honored to receive the Emerging Company of the Year Award at the @LifeSciencesPA 2026 Annual Dinner & Showcase.
This recognition reflects our team’s persistence and determination to advance new approaches designed to overcome the challenges of treating solid tumors.
English
This week, Dispatch leadership & co-founders shared our story with the MBC BioLabs community in SF to discuss how we’re advancing a first-in-class platform to overcome targeting and resistance challenges in treating solid tumors. Thanks for hosting!
English
Dispatch Bio retweetledi
Congrats to PICI Center Director Carl June, MD, named a Citizen of the Year by @PhilaCitizen. From CAR-T breakthroughs to co-launching @DispatchBio, a PICI portfolio company, Carl is pushing cancer innovation toward a future of universal cancer therapies.
Institute for Immunology and Immune Health (I3H)@UPenn_I3H
Congrats to Carl June, MD, named a Citizen of the Year (Disruptor of the Year) by @PhilaCitizen. From pioneering CAR-T therapy to launching @DispatchBio—rooted in Philly’s "Cellicon Valley"—his research continues to push the boundaries of cancer treatment. thephiladelphiacitizen.org/meet-the-citiz…
English
At #AACRIO26, our co-founder & CPO will highlight our clinical-stage Flare platform.
Flare uses a tumor-specific virus to paint a universal synthetic antigen on tumor cells–enabling precise T cell recognition while reshaping the tumor microenvironment to support immune activity.
English
The ECI Advancing Manufacture of Cell & Gene Therapies meeting reinforced the importance of product understanding & analytical rigor in scaling complex therapies–principles that align with how we aim to advance science & engineer a universal treatment across solid tumors.
English
Dispatch Bio retweetledi
Congrats to Carl June, MD, named a Citizen of the Year (Disruptor of the Year) by @PhilaCitizen. From pioneering CAR-T therapy to launching @DispatchBio—rooted in Philly’s "Cellicon Valley"—his research continues to push the boundaries of cancer treatment. thephiladelphiacitizen.org/meet-the-citiz…
English
We look forward to continuing this dialogue at the upcoming #IO360Summit, where Barbra will participate in discussions focused on advancing next-generation immuno-oncology strategies and translating scientific progress into clinical impact. Register here: reg.theconferenceforum.org/event/io360-20…
English
In a recent interview, our CSO, Barbra Sasu, shared insights on Dispatch’s novel approach to overcoming longstanding challenges in solid tumors, as well as insights from her extensive experience in drug discovery. Read the full interview here: theconferenceforum.org/editorial/comb…
English
A cancer diagnosis can turn a person’s world upside down. On #WorldCancerDay & in solidarity with patients, families, caregivers, & clinicians, we’ve turned our logo upside down. We share in this community’s commitment to working toward better treatment options & real hope.
English
View the full schedule here: ssl.linklings.net/conferences/ce…
English
Dispatch is participating in the ECI Advancing Manufacture of Cell & Gene Therapies meeting next week, presenting on how analytical rigor & product understanding can enable control strategies, overcome development challenges, and lead to accessible therapies for patients.
English